Vectibix: A Comprehensive Guide to its Uses, Dosage, Demographic, Side Effects, Interactions, and Generic Options Vectibix is a medication approved by the US Food and Drug Administration (FDA) as a type of targeted therapy to treat metastatic colorectal cancer (cancer that has spread to other parts of the body). Its active ingredient is panitumumab, a monoclonal antibody that selectively binds to the epidermal growth factor receptor (EGFR) that is overexpressed in some cancer cells. In this article, we will discuss Vectibix in detail, including its uses, dosage, demographic, side effects, interactions, and generic options. Uses Vectibix is used in combination with chemotherapy to treat patients with metastatic colorectal cancer that expresses wild-type KRAS (a genetic mutation present in about 40% of patients with metastatic colorectal cancer). It is also indicated as monotherapy for patients with metastatic colorectal cancer who have failed prior chemotherapy or are intolerant to it. Vectibix is not effective in patients whose cancer has the mutated KRAS gene. Dosage Vectibix is given by a healthcare provider through an injection into a vein (intravenous infusion). The recommended dose is 6 mg/kg of body weight, once every two weeks. The infusion should take about 60 minutes. The dose may need to be adjusted based on the patient's body weight, response to treatment, and side effects. Demographic Vectibix is approved for use in adults with metastatic colorectal cancer that expresses wild-type KRAS. It is not recommended for use in children or pregnant or breastfeeding women, as the safety and effectiveness of the drug have not been established in these populations. Side Effects Like any medication, Vectibix may cause side effects. The most common side effects of Vectibix include skin rash or dryness, fatigue, nausea, diarrhea, and infusion reactions (fever, chills, flushing, shortness of breath). More serious side effects may include severe skin reactions (such as Stevens-Johnson syndrome), lung problems, eye problems, and intestinal perforation (a tear or hole in the wall of the intestine). Patients should report any new or worsening symptoms to their healthcare provider promptly. Interactions Vectibix may interact with other drugs that are metabolized by the liver or affect liver function. It is important for patients to inform their healthcare provider of all medications they are taking, including over-the-counter drugs, herbal supplements, and vitamins, before starting Vectibix treatment. Generic Options There are currently no generic versions of Vectibix available in the United States. However, a biosimilar product, called Kanjinti, was approved by the FDA in 2019 for the same indications as Vectibix. Biosimilars are highly similar versions of an already approved biological product that have no clinically meaningful differences in terms of safety and effectiveness. Conclusion In summary, Vectibix is a targeted therapy that is used to treat metastatic colorectal cancer that expresses wild-type KRAS. It is given by a healthcare provider through an intravenous infusion, and the recommended dose is 6 mg/kg of body weight administered once every two weeks. Vectibix may cause side effects, including skin rash or dryness, fatigue, nausea, and diarrhea. Patients should report any new or worsening symptoms to their healthcare provider promptly. There are no generic versions of Vectibix available in the US, but a biosimilar product, Kanjinti, was recently approved for the same indications. As with any medication, patients should discuss their treatment options with their healthcare provider to determine the best course of action for their individual needs.